These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 17927611)

  • 1. The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore.
    Lacey LF; Gane E
    J Viral Hepat; 2007 Nov; 14(11):751-66. PubMed ID: 17927611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of the cost-effectiveness of antiviral therapies in chronic hepatitis B patients in Korea].
    Kim BK; Kwon SY; Lee CH; Choe WH; Choi HM; Koo HW
    Korean J Hepatol; 2009 Mar; 15(1):25-41. PubMed ID: 19346783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review and economic evaluation of adefovir dipivoxil and pegylated interferon-alpha-2a for the treatment of chronic hepatitis B.
    Takeda A; Jones J; Shepherd J; Davidson P; Price A
    J Viral Hepat; 2007 Feb; 14(2):75-88. PubMed ID: 17244247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluation of chronic hepatitis B treatments in Taiwan.
    Lacey L; Chien RN; Chuang WL; Pwu RF
    J Gastroenterol Hepatol; 2008 Apr; 23(4):571-9. PubMed ID: 18397486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B.
    Veenstra DL; Sullivan SD; Clarke L; Iloeje UH; Tafesse E; Di Bisceglie A; Kowdley KV; Gish RG
    Pharmacoeconomics; 2007; 25(11):963-77. PubMed ID: 17960954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis.
    Kanwal F; Gralnek IM; Martin P; Dulai GS; Farid M; Spiegel BM
    Ann Intern Med; 2005 May; 142(10):821-31. PubMed ID: 15897532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [An economic evaluation of different treatments for HBeAg-positive chronic hepatitis B in China].
    Larry L; Lu XZ; Alison T
    Zhonghua Gan Zang Bing Za Zhi; 2007 Jun; 15(6):431-6. PubMed ID: 17594808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of peginterferon alpha-2a compared with lamivudine treatment in patients with HBe-antigen-positive chronic hepatitis B in the United Kingdom.
    Veenstra DL; Sullivan SD; Dusheiko GM; Jacobs M; Aledort JE; Lewis G; Patel KK
    Eur J Gastroenterol Hepatol; 2007 Aug; 19(8):631-8. PubMed ID: 17625431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of peginterferon alpha-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan.
    Sullivan SD; Veenstra DL; Chen PJ; Chang TT; Chuang WL; Tsai C; Patel K
    J Gastroenterol Hepatol; 2007 Sep; 22(9):1494-9. PubMed ID: 17716353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HBeAg-negative chronic hepatitis B: cost-effectiveness of peginterferon alfa-2a compared to lamivudine in Taiwan.
    Veenstra DL; Sullivan SD; Lai MY; Lee CM; Tsai CM; Patel KK
    Value Health; 2008; 11(2):131-8. PubMed ID: 18380625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis.
    Wu B; Li T; Chen H; Shen J
    Value Health; 2010 Aug; 13(5):592-600. PubMed ID: 20561341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of treatments for chronic hepatitis B.
    Wiens A; Lenzi L; Venson R; Pedroso ML; Correr CJ; Pontarolo R
    Braz J Infect Dis; 2013; 17(4):418-26. PubMed ID: 23849851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand.
    Tantai N; Chaikledkaew U; Tanwandee T; Werayingyong P; Teerawattananon Y
    BMC Health Serv Res; 2014 Apr; 14():170. PubMed ID: 24731689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness and cost-utility of the treatment of chronic hepatitis B with peginterferon alfa-2a, interferon alfa, and lamivudine in Lithuania.
    Vanagas G; Padaiga Z; Mickevičienė A
    Medicina (Kaunas); 2010; 46(12):835-42. PubMed ID: 21532288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion.
    Cao ZH; Ma LN; Zhang HW; Liu YL; Chen XY
    J Dig Dis; 2013 Aug; 14(8):446-50. PubMed ID: 23615131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective.
    Dakin H; Sherman M; Fung S; Fidler C; Bentley A
    Pharmacoeconomics; 2011 Dec; 29(12):1075-91. PubMed ID: 22077579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China.
    Wu B; Shen J; Cheng H
    BMC Health Serv Res; 2012 Nov; 12():385. PubMed ID: 23137013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness and Clinical Impact of Antiviral Strategies of HBeAg-Positive and -Negative Chronic Hepatitis B.
    Oyagüez I; Buti M; Brosa M; Rueda M; Casado MA
    Ann Hepatol; 2017; 16(3):358-365. PubMed ID: 28425405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic hepatitis B treatment: the cost-effectiveness of interferon compared to lamivudine.
    Almeida AM; da Silva AL; Cherchiglia ML; Andrade EI; de Oliveira GL; Acurcio Fde A
    Value Health; 2011; 14(5 Suppl 1):S24-8. PubMed ID: 21839893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.